Diabetes, from Medtronic automated system for insulin infusion

–

Published on: 10/29/2020 13:57

A new automated system for insulin infusion. Medtronic has announced the launch of the MiniMed ™ 780G in Italy, just days before World Diabetes Day on November 14th. Thus opens – reads a note – a new frontier for the management of diabetes: “an advanced hybrid closed loop system (” Ahcl ‘), integrated and of the latest generation, capable of automating the administration of both basal insulin that of boluses for the correction of glycemic rises every 5 minutes, in patients aged 7 to 80 with type 1 diabetes.

According to data published in 2017 by the World Diabetes Federation, around the world there are 425 million people living with diabetes (1 in 11 adults) and 212 million (1 in 2 adults) do not know they have it. In Italy, Istat estimates that in 2016 there were over 3 million and 200 thousand people with diabetes, that is 5.3% of the entire population. Of these, about 10% have type 1 diabetes.

“MiniMed ™ 780G is able to offer additional help to these patients, reducing the effort required to manage the therapy and doing it more peacefully, keeping blood sugar under control more easily by intervening autonomously on delivery to compensate for inaccuracies in the estimate carbohydrates and automatically correcting high blood sugar levels. It is a technology that helps you live your time with greater freedom to be able to dedicate yourself to what you love most “, highlights the company.

Receiving a diagnosis of type 1 diabetes can change people’s lives, forced for life – since the disease occurs mainly in childhood and adolescence – to manage glycemic peaks as much as possible within target values . In fact, it is a daily challenge for patients to have to accurately calculate the amount of carbohydrates in each meal in order to determine the correct amount of bolus insulin.

“MiniMed ™ 780G is a further step towards the so-called ‘closed loop system’, advanced integrated – explained Dario Pitocco, director in charge of the Diabetes Departmental Operational Unit, Agostino Gemelli Irccs Polyclinic Foundation, and associate professor of Endocrinology at the university Cattolica – The purpose of the device is to make the glycemic trend, over 24 hours, as stable as possible, with the achievement of a very high percentage of the ‘time in range’, that is the percentage of time that the patient spends within the optimal blood glucose range “.

“With the continuous monitoring of blood glucose – he adds – the therapeutic objectives in the management of diabetes have changed: with the achievement of a high percentage of time in range, at least 70%, it becomes a fundamental goal to make the patient’s quality of life with best possible type 1 diabetes ”.

MiniMed ™ 780G is the latest example of how Medtronic has always been committed to transforming diabetes management by offering innovative technologies for greater freedom and better wellbeing, uses intelligent algorithms to improve patient outcomes and simplify decisions for people who live with diabetes, leveraging in-depth data analysis and the opportunities of artificial intelligence.

“Today we announce a further step forward in the management of type 1 diabetes – highlights Luigi Morgese, business director of the Diabetes Division – able to simplify the daily control of therapy and improve the quality of life of thousands of patients. The new MiniMed ™ 780G it intervenes autonomously in the supply of insulin to compensate for inaccuracies in the estimation of carbohydrates and automatically correct high blood sugar levels. We intend to reduce the patient’s effort in managing the therapy, thanks to the automation offered by this new system that can manage patients even remotely . A fundamental feature in this phase of the pandemic, which allows greater control, in real time, of the glycemic trend by the doctor and family members, validated by scientific evidence. All this thanks to connectivity, the availability of constantly updated data and analyzes. , and the possibility of instructing remote use on platforms virtual certified, dedicated “, he concludes.

–

REPRODUCTION RESERVED © Copyright Adnkronos.